MX2022013864A - Moduladores del receptor cannabinoide tipo 2 (cb2) y usos de los mismos. - Google Patents
Moduladores del receptor cannabinoide tipo 2 (cb2) y usos de los mismos.Info
- Publication number
- MX2022013864A MX2022013864A MX2022013864A MX2022013864A MX2022013864A MX 2022013864 A MX2022013864 A MX 2022013864A MX 2022013864 A MX2022013864 A MX 2022013864A MX 2022013864 A MX2022013864 A MX 2022013864A MX 2022013864 A MX2022013864 A MX 2022013864A
- Authority
- MX
- Mexico
- Prior art keywords
- cannabinoid receptor
- modulators
- receptor type
- modulating
- compounds
- Prior art date
Links
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 title 1
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 title 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 abstract 6
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente descripción se describen compuestos, composiciones y métodos para modular el receptor cannabinoide 2 (CB2) con los compuestos y composiciones descritos en la presente descripción. También se describen métodos para tratar enfermedades o afecciones que están mediadas por la acción del receptor cannabinoide 2 (CB2) o que se benefician de la modulación del receptor cannabinoide 2 (CB2).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063020489P | 2020-05-05 | 2020-05-05 | |
US202063054096P | 2020-07-20 | 2020-07-20 | |
PCT/US2021/030838 WO2021226206A2 (en) | 2020-05-05 | 2021-05-05 | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013864A true MX2022013864A (es) | 2023-03-09 |
Family
ID=76181225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013864A MX2022013864A (es) | 2020-05-05 | 2021-05-05 | Moduladores del receptor cannabinoide tipo 2 (cb2) y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11564928B1 (es) |
EP (1) | EP4146345A2 (es) |
JP (1) | JP2023526783A (es) |
KR (1) | KR20230041654A (es) |
CN (1) | CN115835909A (es) |
AU (1) | AU2021266732A1 (es) |
BR (1) | BR112022022335A2 (es) |
CA (1) | CA3181538A1 (es) |
IL (1) | IL297908A (es) |
MX (1) | MX2022013864A (es) |
WO (1) | WO2021226206A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021266732A1 (en) * | 2020-05-05 | 2023-01-05 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (CB2) modulators and uses thereof |
TW202325306A (zh) * | 2021-09-02 | 2023-07-01 | 美商天恩治療有限公司 | 改良免疫細胞之生長及功能的方法 |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
CN117624134B (zh) * | 2024-01-26 | 2024-05-03 | 南昌市第一医院 | 一种靶向降解hdac4的化合物及其制备方法和应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2988739B2 (ja) * | 1990-04-16 | 1999-12-13 | 協和醗酵工業株式会社 | 1,8−ナフチリジン−2−オン誘導体 |
DE4227747A1 (de) | 1992-08-21 | 1994-02-24 | Basf Ag | Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
CA2433158C (en) * | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
DE602004024814D1 (de) | 2003-11-04 | 2010-02-04 | Merck & Co Inc | Substituierte naphthyridinonderivate |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
US8048894B2 (en) | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
GB0800855D0 (en) | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
JP2013518907A (ja) * | 2010-02-08 | 2013-05-23 | アラーガン インコーポレイテッド | カンナビノイド−2作動薬として有用なピリダジン誘導体 |
WO2013165898A2 (en) | 2012-05-01 | 2013-11-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting resolvases |
RU2723050C2 (ru) | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
AU2014405919B2 (en) | 2014-09-11 | 2020-02-20 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80 (B7-1)/PD-Li protein/protein interactions |
WO2016041511A1 (en) | 2014-09-19 | 2016-03-24 | Yen-Ta Lu | Benzo-heterocyclic compounds and their applications |
MX2017011612A (es) | 2015-03-10 | 2018-03-23 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores. |
CA2979145A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
EP3267998A4 (en) | 2015-03-10 | 2018-12-19 | Aurigene Discovery Technologies Limited | 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
HRP20220258T1 (hr) | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
SG11201706901TA (en) | 2015-03-10 | 2017-09-28 | Aurigene Discovery Tech Ltd | Therapeutic cyclic compounds as immunomodulators |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2017068349A1 (en) * | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
CA3004083A1 (en) | 2015-11-04 | 2017-05-11 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3390361B1 (en) | 2015-12-17 | 2022-03-16 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
KR20180100585A (ko) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | 면역조절제로서의 헤테로사이클릭 화합물 |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
US9798514B2 (en) | 2016-03-09 | 2017-10-24 | Spotify Ab | System and method for color beat display in a media content environment |
US20190062272A1 (en) | 2016-04-13 | 2019-02-28 | Capten Therapeutics Inc. | Small molecules for immunogenic treatment of cancer |
TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
JP6905053B2 (ja) | 2016-05-23 | 2021-07-21 | 中国医学科学院薬物研究所Institute Of Materia Medica, Chinese Academy Of Medical Sciences | ベンジルフェニルエーテル誘導体、その調製方法、並びにその医薬組成物及び使用 |
EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
RU2018145184A (ru) | 2016-05-26 | 2020-06-26 | Мерк Патент Гмбх | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования |
LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
WO2018009505A1 (en) | 2016-07-08 | 2018-01-11 | Bristol-Myers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
EP3493804A1 (en) | 2016-08-03 | 2019-06-12 | Arising International, Inc. | Symmetric or semi-symmetric compounds useful as immunomodulators |
US10563620B2 (en) | 2016-08-12 | 2020-02-18 | Rolls-Royce North American Technologies Inc. | Expandable exhaust cone |
WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10734026B2 (en) | 2016-09-01 | 2020-08-04 | Facebook, Inc. | Systems and methods for dynamically providing video content based on declarative instructions |
US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
SG11202000431PA (en) | 2017-07-18 | 2020-02-27 | Nuvation Bio Inc | 1,8-naphthyridinone compounds and uses thereof |
CA3091015C (en) | 2018-02-13 | 2023-02-21 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
AU2021266732A1 (en) * | 2020-05-05 | 2023-01-05 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (CB2) modulators and uses thereof |
-
2021
- 2021-05-05 AU AU2021266732A patent/AU2021266732A1/en active Pending
- 2021-05-05 WO PCT/US2021/030838 patent/WO2021226206A2/en unknown
- 2021-05-05 IL IL297908A patent/IL297908A/en unknown
- 2021-05-05 JP JP2022567080A patent/JP2023526783A/ja active Pending
- 2021-05-05 BR BR112022022335A patent/BR112022022335A2/pt unknown
- 2021-05-05 MX MX2022013864A patent/MX2022013864A/es unknown
- 2021-05-05 EP EP21728701.0A patent/EP4146345A2/en active Pending
- 2021-05-05 CA CA3181538A patent/CA3181538A1/en active Pending
- 2021-05-05 CN CN202180047613.9A patent/CN115835909A/zh active Pending
- 2021-05-05 KR KR1020227042067A patent/KR20230041654A/ko active Search and Examination
-
2022
- 2022-03-10 US US17/691,991 patent/US11564928B1/en active Active
- 2022-10-05 US US17/960,625 patent/US11957689B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20230143502A1 (en) | 2023-05-11 |
KR20230041654A (ko) | 2023-03-24 |
BR112022022335A2 (pt) | 2023-01-10 |
CN115835909A (zh) | 2023-03-21 |
WO2021226206A3 (en) | 2021-12-16 |
EP4146345A2 (en) | 2023-03-15 |
IL297908A (en) | 2023-01-01 |
CA3181538A1 (en) | 2021-11-11 |
WO2021226206A2 (en) | 2021-11-11 |
JP2023526783A (ja) | 2023-06-23 |
AU2021266732A1 (en) | 2023-01-05 |
US11564928B1 (en) | 2023-01-31 |
US11957689B2 (en) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013864A (es) | Moduladores del receptor cannabinoide tipo 2 (cb2) y usos de los mismos. | |
MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
CR20210592A (es) | Moduladores de la vía integrada del estrés | |
PH12020550523A1 (en) | Modulators of the integrated stress pathway | |
MX2020007899A (es) | Compuestos. | |
BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
MX2023009561A (es) | Moduladores de profarmacos de la via de estres integrada. | |
PH12020550524A1 (en) | Modulators of the integrated stress pathway | |
WO2019090085A8 (en) | Modulators of the integrated stress pathway | |
MA44861B1 (fr) | Modulateurs de la voie de réponse intégrée au stress | |
AU2017260374A1 (en) | Modulators of the integrated stress pathway | |
MX2023004870A (es) | Moduladores de la via integrada del estres. | |
CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
MX2021008400A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
MX2021008364A (es) | Amidas de pirrolidina iii sustituidas. | |
MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
CA3095040A1 (en) | Treating diseases via targeted modulation of gene signaling networks | |
WO2021061707A8 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
MX2023005928A (es) | Moduladores de malt-1. |